Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet
Authors:
- Craig LeonardiCLCraig Leonardi
- Richard G. LangleyRLRichard G. Langley
- Kim PappKPKim Papp
- Stephen K. TyringSTStephen K. Tyring
- Norman WaselNWNorman Wasel
- Ronald VenderRVRonald Vender
- Kristina UnnebrinkKUKristina Unnebrink
- Shiraz R. GuptaSGShiraz R. Gupta
- Wendell C. ValdecantosWVWendell C. Valdecantos
- Jerry BagelJBJerry Bagel
Open Access
- 1 April 2011
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 147 (4) , 429-436
Abstract
Moderate to severe chronic plaque psoriasis of the hands and/or feet occurs infrequently in the general population; however, this subset of psoriasis vulgaris is of unique clinical interest because of its disproportionately negative impact on quality of life, despite the relatively small body surface area (BSA) affected.1-5 Treatment for most patients with hand and/or foot psoriasis, including the subset of patients with involvement of palms and/or soles (palmoplantar disease), is unsatisfactory, since topical therapies and/or phototherapy are sometimes ineffective and inconvenient and systemic therapies are limited by potential toxic effects.6Keywords
This publication has 17 references indexed in Scilit:
- A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patientsJournal of the European Academy of Dermatology and Venereology, 2009
- Palmoplantar psoriasis: A phenotypical and clinical review with introduction of a new quality-of-life assessment toolJournal of the American Academy of Dermatology, 2009
- Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 casesJournal of Dermatological Treatment, 2009
- The Enigmatic Development of Psoriasis and Psoriasiform Lesions During Anti-TNF Therapy: A ReviewSeminars in Arthritis and Rheumatism, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)British Journal of Dermatology, 2007
- Psoriasiform and pustular eruption induced by infliximabThe Journal of Dermatology, 2007
- Psoriasis induced by anti–tumor necrosis factor therapy: A paradoxical adverse reactionArthritis & Rheumatism, 2005
- Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practiceJournal of the American Academy of Dermatology, 2003
- Palmoplantar Lesions in Psoriasis: A Study of 3065 PatientsActa Dermato-Venereologica, 2002